Vazyme(SH:688105) Xin Lang Cai Jing·2025-09-16 01:35Group 1 - The core business of the company includes research and development of functional proteins and high molecular organic materials, with a revenue composition of 81.86% from biological reagents, 9.99% from diagnostic reagents, and smaller contributions from other segments [2] - As of June 30, the company reported a total revenue of 606 million yuan for the first half of 2025, representing a year-on-year decrease of 6.63%, and a net profit attributable to shareholders of 3.13 million yuan, down 80.63% year-on-year [2] - The company has a total of 8,596 shareholders, which is an increase of 2.37% compared to the previous period, with an average of 46,269 circulating shares per shareholder, a decrease of 2.31% [2] Group 2 - The company has distributed a total of 731 million yuan in dividends since its A-share listing, with 611 million yuan distributed over the past three years [3] Group 3 - On September 15, the company's stock price fell by 1.71%, with a trading volume of 75.77 million yuan, and a net financing purchase of 4.56 million yuan for the day [1] - The financing balance as of September 15 is 112 million yuan, accounting for 1.23% of the circulating market value, which is above the 90th percentile level over the past year [1] - The company had a low short-selling balance of 35.03 million yuan, with a short-selling volume of 8,500 shares on September 15 [1]